Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C12H30Al8O51S8.H2O.AlH3O3 |
Molecular Weight | 1558.727 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O[Al](O)O.[H][C@]2(O[C@]1(COS(=O)(=O)O[Al](O)O)O[C@H](COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O)O[C@H](COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@H]2OS(=O)(=O)O[Al](O)O
InChI
InChIKey=IPLJAZDIICJQEL-JTJNLBSYSA-A
InChI=1S/C12H22O35S8.9Al.20H2O/c13-48(14,15)37-1-4-6(43-51(22,23)24)8(45-53(28,29)30)9(46-54(31,32)33)11(40-4)42-12(3-39-50(19,20)21)10(47-55(34,35)36)7(44-52(25,26)27)5(41-12)2-38-49(16,17)18;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/h4-11H,1-3H2,(H,13,14,15)(H,16,17,18)(H,19,20,21)(H,22,23,24)(H,25,26,27)(H,28,29,30)(H,31,32,33)(H,34,35,36);;;;;;;;;;20*1H2/q;9*+3;;;;;;;;;;;;;;;;;;;;/p-27/t4-,5-,6-,7-,8+,9-,10+,11-,12+;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/m1............................./s1
Molecular Formula | AlH3O3 |
Molecular Weight | 78.0036 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C12H30Al8O51S8 |
Molecular Weight | 1462.708 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | H2O |
Molecular Weight | 18.0153 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.drugs.com/pro/sucralfate.html | https://www.ncbi.nlm.nih.gov/pubmed/8944383
Curator's Comment: description was created based on several sources, including
https://www.drugs.com/pro/sucralfate.html | https://www.ncbi.nlm.nih.gov/pubmed/8944383
Sucralfate (trade name CARAFATE) is a medication primarily taken to treat active duodenal ulcers. Sucralfate is also used for the treatment of gastroesophageal reflux disease (GERD) and stress ulcers. Sucralfate is a sucrose sulfate-aluminium complex that binds to the ulcer, creating a physical barrier that protects the gastrointestinal tract from stomach acid and prevents the degradation of mucus. Sucralfate is only minimally absorbed from the gastrointestinal tract. The small amounts of the sulfated disaccharide that are absorbed are excreted primarily in the urine.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: degradation of mucus |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CARAFATE Approved UseSucralfate is indicated in: Short-term treatment (up to 8 weeks) of active duodenal ulcer. While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. Launch Date1981 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.27 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9257738/ |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUCRALFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
35 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9257738/ |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUCRALFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
20 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9257738/ |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUCRALFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Sample Use Guides
The recommended adult oral dosage for duodenal ulcer is 1 g (10 mL/2
teaspoons) four times per day. CARAFATE should be administered on an empty stomach.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8944383
For sustained release of sucralfate and bFGF, implants were coated with hydron. Suspension no. 1 contained 100 ml of 95% ethanol mixed with 0.12 mg/ml of hydron. Next, 60 ml of premixed suspension no. 1 was prepared with 10 mg/ml of sucralfate. Then, 20 ml of premixed suspension no. 2 was mixed with 12 ng/ml of bFGF, which was prepared with 100 jul of sterile saline. Finally, implants were dipped into the suspension for 5 min and then dried for 8 h before being placed in the media in sterile Petri dishes.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:44:50 GMT 2023
by
admin
on
Sat Dec 16 16:44:50 GMT 2023
|
Record UNII |
XX73205DH5
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C797
Created by
admin on Sat Dec 16 16:44:50 GMT 2023 , Edited by admin on Sat Dec 16 16:44:50 GMT 2023
|
||
|
WHO-ATC |
A02BX02
Created by
admin on Sat Dec 16 16:44:50 GMT 2023 , Edited by admin on Sat Dec 16 16:44:50 GMT 2023
|
||
|
NDF-RT |
N0000175801
Created by
admin on Sat Dec 16 16:44:50 GMT 2023 , Edited by admin on Sat Dec 16 16:44:50 GMT 2023
|
||
|
FDA ORPHAN DRUG |
73893
Created by
admin on Sat Dec 16 16:44:50 GMT 2023 , Edited by admin on Sat Dec 16 16:44:50 GMT 2023
|
||
|
FDA ORPHAN DRUG |
47090
Created by
admin on Sat Dec 16 16:44:50 GMT 2023 , Edited by admin on Sat Dec 16 16:44:50 GMT 2023
|
||
|
NDF-RT |
N0000007683
Created by
admin on Sat Dec 16 16:44:50 GMT 2023 , Edited by admin on Sat Dec 16 16:44:50 GMT 2023
|
||
|
NDF-RT |
N0000007683
Created by
admin on Sat Dec 16 16:44:50 GMT 2023 , Edited by admin on Sat Dec 16 16:44:50 GMT 2023
|
||
|
WHO-VATC |
QA02BX02
Created by
admin on Sat Dec 16 16:44:50 GMT 2023 , Edited by admin on Sat Dec 16 16:44:50 GMT 2023
|
||
|
FDA ORPHAN DRUG |
41089
Created by
admin on Sat Dec 16 16:44:50 GMT 2023 , Edited by admin on Sat Dec 16 16:44:50 GMT 2023
|
||
|
NCI_THESAURUS |
C2080
Created by
admin on Sat Dec 16 16:44:50 GMT 2023 , Edited by admin on Sat Dec 16 16:44:50 GMT 2023
|
||
|
LIVERTOX |
903
Created by
admin on Sat Dec 16 16:44:50 GMT 2023 , Edited by admin on Sat Dec 16 16:44:50 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
54182-58-0
Created by
admin on Sat Dec 16 16:44:50 GMT 2023 , Edited by admin on Sat Dec 16 16:44:50 GMT 2023
|
PRIMARY | |||
|
7055
Created by
admin on Sat Dec 16 16:44:50 GMT 2023 , Edited by admin on Sat Dec 16 16:44:50 GMT 2023
|
PRIMARY | |||
|
SUCRALFATE
Created by
admin on Sat Dec 16 16:44:50 GMT 2023 , Edited by admin on Sat Dec 16 16:44:50 GMT 2023
|
PRIMARY | |||
|
SUB04613MIG
Created by
admin on Sat Dec 16 16:44:50 GMT 2023 , Edited by admin on Sat Dec 16 16:44:50 GMT 2023
|
PRIMARY | |||
|
2723
Created by
admin on Sat Dec 16 16:44:50 GMT 2023 , Edited by admin on Sat Dec 16 16:44:50 GMT 2023
|
PRIMARY | |||
|
D013392
Created by
admin on Sat Dec 16 16:44:50 GMT 2023 , Edited by admin on Sat Dec 16 16:44:50 GMT 2023
|
PRIMARY | |||
|
C848
Created by
admin on Sat Dec 16 16:44:50 GMT 2023 , Edited by admin on Sat Dec 16 16:44:50 GMT 2023
|
PRIMARY | |||
|
10156
Created by
admin on Sat Dec 16 16:44:50 GMT 2023 , Edited by admin on Sat Dec 16 16:44:50 GMT 2023
|
PRIMARY | RxNorm | ||
|
3926
Created by
admin on Sat Dec 16 16:44:50 GMT 2023 , Edited by admin on Sat Dec 16 16:44:50 GMT 2023
|
PRIMARY | |||
|
CHEMBL2367706
Created by
admin on Sat Dec 16 16:44:50 GMT 2023 , Edited by admin on Sat Dec 16 16:44:50 GMT 2023
|
PRIMARY | |||
|
DB00364
Created by
admin on Sat Dec 16 16:44:50 GMT 2023 , Edited by admin on Sat Dec 16 16:44:50 GMT 2023
|
PRIMARY | |||
|
Sucralfate
Created by
admin on Sat Dec 16 16:44:50 GMT 2023 , Edited by admin on Sat Dec 16 16:44:50 GMT 2023
|
PRIMARY | |||
|
XX73205DH5
Created by
admin on Sat Dec 16 16:44:50 GMT 2023 , Edited by admin on Sat Dec 16 16:44:50 GMT 2023
|
PRIMARY | |||
|
4106
Created by
admin on Sat Dec 16 16:44:50 GMT 2023 , Edited by admin on Sat Dec 16 16:44:50 GMT 2023
|
PRIMARY | |||
|
m10280
Created by
admin on Sat Dec 16 16:44:50 GMT 2023 , Edited by admin on Sat Dec 16 16:44:50 GMT 2023
|
PRIMARY | Merck Index | ||
|
100000091545
Created by
admin on Sat Dec 16 16:44:50 GMT 2023 , Edited by admin on Sat Dec 16 16:44:50 GMT 2023
|
PRIMARY | |||
|
259-018-4
Created by
admin on Sat Dec 16 16:44:50 GMT 2023 , Edited by admin on Sat Dec 16 16:44:50 GMT 2023
|
PRIMARY | |||
|
DTXSID1048966
Created by
admin on Sat Dec 16 16:44:50 GMT 2023 , Edited by admin on Sat Dec 16 16:44:50 GMT 2023
|
PRIMARY | |||
|
XX73205DH5
Created by
admin on Sat Dec 16 16:44:50 GMT 2023 , Edited by admin on Sat Dec 16 16:44:50 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR | |||
|
PARENT -> SALT/SOLVATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |